Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.

ESC Heart Fail · 2022 · PMC9715790 · PMID 35702942

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Patients who tolerated the maximum dose of Sac/Val also showed a positive trend in term of LV reverse remodelling ( Figure 3 ), and of a NYHA class <3 at follow‐up (Supporting Information, Figure S1 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.